Slide 1: 2025 Interim Results Presentation
2025 Interim Results Presentation For six months ending 31 March 2025 May 2025
Slide 2: Nonregulated Disclaimer
Nonregulated Disclaimer This presentation is incomplete without reference to, and should be viewed solely in conjunction with, the oral briefing which accompanies it. The information in this presentation is subject to updating, revision and amendment. The information in this presentation, which incl
Slide 3: Neuroscience R&D complexity and IXICO's platform
Neuroscience R&D is complex, technically challenging, highly regulated and requires deep expertise... ...IXICO’s technology platform and team of experts uniquely enables biopharma companies to simplify that complexity and support success in patient outcomes. 3
Slide 4: IXICO at a glance
IXICO at a glance Leader in imaging and biomarker analytics combining AI precision medicine with deep neuroscience expertise Alzheimer's Disease IXICO AI PLATFORM Imaging biomarkers Huntington's Disease Drug safety Multiple Sclerosis Patient Parkinson's Trial management Disease eligibility Other: De
Slide 5: Growth Strategy: Innovate | Lead | Scale
Growth Strategy: Innovate | Lead | Scale Broadening and deepening the commercial opportunity to drive growth • DIFFERENTIATION - novel biomarker analytics market leadership • TECHNOLOGY EXPANSION - next-gen-AI-powered imaging ACCELERATE Pipeline expansion INNOVATE biomarker platform and access to di
Slide 6: Executing the strategy - H1 2025 Highlights
Executing the strategy - H1 2025 Highlights • Successful deployments of next generation platform • Further technology development & new features • New product AD/PD offerings for H2 2025 Revenues up 26% on H1-24 • Multimodal momentum – AD blood-based biomarker validation INNOVATE • Further external
Slide 7: Financial Results
Financial Results 7
Slide 8: H1 revenue growth drives gross margin & EBITDA uplift
H1 revenue growth drives gross margin & EBITDA uplift Revenues (£m) Gross Margin (%) EBITDA (£m) -0.6 -0.7 -1.3 3.2 3.2 2.5 50 46 40 H1-23 H1-24 H1-25 H1-23 H1-24 H1-25 H1-23 H1-24 H1-25 ▪ 26% revenues growth on H1-24 ▪ Gross margins reflect revenue increase and ▪ EBITDA improvement reflects ▪ Refle
Slide 9: Well capitalised - Next generation platform deployed
Well capitalised - Next generation platform deployed Cash (£m) Capital investment (£m) Net Assets (£m) 0.9 5.0 11.4 12.3 4.0 10.0 2.5 0.3 0.3 31-Mar-23 31-Mar-24 31-Mar-25 H1-23 H1-24 H1-25 31-Mar-23 31-Mar-24 31-Mar-25 ▪ £5.0m debt-free cash position ▪ Leading technology platform, following ▪ Stron
Slide 10: Order Book (£13.1m) provides platform for growth
Order Book (£13.1m) provides platform for growth £9.7m of contract wins/extensions in the past year; c.100% of FY25 revenue target contracted 6.4 9.7 15.3 12.7 13.1 12.7 13.1 2.9 31-Mar-24 30-Sep-24 31-Mar-25 31-Mar-24 Revenues Client trial Trial wins 31-Mar-25 descopes and fx ▪ £13.1m of future yea
Slide 11: Diversified order book with multiple 'shots on goal'
Diversified order book with multiple ‘shots on goal’ By clinical trial phase By therapeutic indication 0.3 1.5 2.1 (2) (2) 3.2 (5) 5.0 (8) (6) (8) 2.4 (6) (5) 0.6 (1) (1) 4.0 7.2 (10) (11) (10) £m/(#) £m/(#) 1 2 3 NH Other AD HD PD Other ▪ 17 clients and 25 projects in our orderbook at 31 March 2025
Slide 12: H2 Trading & Summary
ing & Summary | H2 Trad 12
Slide 13: INNOVATE - Product roadmap
INNOVATE - Product roadmap New biomarker products demonstrate expertise, market differentiation and broadened commercial opportunities PRODUCT Vascular abnormities Neuromelanin INNOVATION ID & measurement measurement VASCULAR NEUROMELANIN BIOMARKER #1 BIOMARKER FURTHER FURTHER VASCULAR INFLAMMATION
Slide 14: LEAD – IXICO's thought leadership and impact
LEAD – IXICO’s thought leadership and impact Healthy AD pipeline with new medical / commercial resources generating more opportunities Footprint expansion Thought Leadership Impact New Commercial leader Ops team members The significance of the North American market 44% of global AD clinical trials 1
Slide 15: SCALE: Platform innovation progress and impact
SCALE: Platform innovation progress and impact Commercial impact of product roadmap and corporate initiatives generating strong pipeline (40% in AD & PD) Total Est. Pipeline Therapeutic Area Platform progress Commercial impact Pipeline market (#) (%) share • Accelerated commercial AD traction 15 29%
Slide 16: SCALE: Resourced for scale
SCALE: Resourced for scale Building a team to deliver technology innovation, scientific thought leadership and commercial presence CEO HR Legal QA/RA CFO / COO CSO / CMO VP, Global CBO CTO Commercial US sales Marketing Int’l Sales IR Corp Dev Existing roles Expanded roles New roles Deepened expertis
Slide 17: SCALE – (IXICO tomorrow) Technology Platform
SCALE – (IXICO tomorrow) Technology Platform Present Pharma R&D Insights (CRO) Fee for Service IXICO PLATFORM TECHNOLOGY Longer term Clinical Diagnostics Clinical Decision Support – Hospitals (through partnerships) Immediate focus Integration with other AI Platforms – Licensing, Strategic Investment
Slide 18: Summary: H1 review & H2 progression
Summary: H1 review & H2 progression Build on H1 positive momentum H1 Achievements H2 Objectives Revenues up 26% on H1-24 Deliver revenues of >£6m 1. Greater diversification of projects 1. Agree contracts that give revenue visibility to across therapeutic areas >75% FY26 revenue target 2. Existing cu
Slide 19: Investment case – Precision Medicine in Neuroscience
Investment case – Precision Medicine in Neuroscience A powerful combination of AI technology and human expertise for clinical trial management and analysis COMMERCIAL MARKET DIVERSIFICATION LEADERSHIP INNOVATE • Leader in HD & rare disease Lead by TECHNOLOGY LEADERSHIP LEAD Science SCALE • Est. 3x l
Slide 20: Thank you
Thank you www.ixico.com